[1] |
Lam MG, de Klerk JM, van Rijk PP, et al.
Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases[J]. Anti cancer Agents Med ChemAnti cancer Agents Med Chem, 2007, 7(4): 381-397.
doi: 10.2174/187152007781058596
|
[2] |
Costa L.
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis[J]. BreastBreast, 2007, 16(Suppl 3): S16-S20.
|
[3] |
Choong PF.
The molecular basis of skeletal metastases[J]. Clin Orthop Relat ResClin Orthop Relat Res, 2003, 415(Suppl): S19-S31.
|
[4] |
Coleman RE, Seaman JJ.
The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases[J]. Semin OncolSemin Oncol, 2001, 28(2 Suppl 6): 11-16.
|
[5] |
Bodei L, Lam M, Chiesa C, et al.
EANM procedure guideline for treatment of refractory metastatic bone pain[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2008, 35(10): 1934-1940.
doi: 10.1007/s00259-008-0841-y
|
[6] |
Gkialas I, Iordanidou L, Galanakis I, et al.
The use of radioisotopes for palliation of metastatic bone pain[J]. JBUONJBUON, 2008, 13(2): 177-183.
|
[7] |
Bauman G, Charette M, Reid R, et al.
Radiopharmaceuticals for the palliation of painful metastasis-a systemic review[J]. Radiother OncolRadiother Oncol, 2005, 75(3): 258-270.
|
[8] |
TripathiM, SinghalT, ChandrasekharN, etal.
Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases[J]. IndianJCancerIndianJCancer, 2006, 43(2): 86-92.
|
[9] |
Baczyk M, Czepczyñski R, Milecki P, et al.
89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma[J]. Nucl Med CommunNucl Med Commun, 2007, 28(4): 245-250.
doi: 10.1097/MNM.0b013e32805b72a0
|
[10] |
Liepe K, Kotzerke J.
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases[J]. Nucl Med CommunNucl Med Commun, 2007, 28(8): 623-630.
doi: 10.1097/MNM.0b013e32825a6adc
|
[11] |
Amato RJ, Hernandez-McClain J, Henary H.
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer[J]. Am J Clin OncolAm J Clin Oncol, 2008, 31(6): 532-538.
doi: 10.1097/COC.0b013e318172aa92
|
[12] |
Pagliaro LC, Delpassand ES, Williams D, et al.
A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases[J]. CancerCancer, 2003, 97(12): 2988-2994.
doi: 10.1002/cncr.11412
|
[13] |
Finlay IG, Mason MD, Shelley M.
Radioisotopes for the palliation of metastatic bone cancer: a systematic review[J]. Lancet OncolLancet Oncol, 2005, 6(6): 392-400.
doi: 10.1016/S1470-2045(05)70206-0
|
[14] |
Lewington VJ.
Bone-seeking radionuclides for therapy[J]. J Nucl MedJ Nucl Med, 2005, 46(Suppl 1): 38S-47S.
|
[15] |
Storto G, Klain M, Paone G, et al.
Combined therapy of 89Sr-and zoledronic acid in patients with painful bone metastases[J]. BoneBone, 2006, 39(1): 35-41.
doi: 10.1016/j.bone.2005.12.004
|
[16] |
Koutsikos J, Leondi A.
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2008, 35(7): 1392-1393.
doi: 10.1007/s00259-008-0759-4
|
[17] |
梁九根, 蒋宁一, 杜建强, 等.
188Re-羟乙基二膦酸与帕米膦酸二钠联合治疗乳腺癌骨转移的临床价值[J]. 中华肿瘤杂志中华肿瘤杂志, 2005, 27(3): 180-182.
doi: 10.3760/j.issn:0253-3766.2005.03.016
|
[18] |
Vassiliou V, Bruland O, Janjan N, et al.
Combining systemic bisphosphonates with palliative external beam radiotherapy or bonetargeted radionuclide therapy: interactions and effectiveness[J]. Clin OncolClin Oncol, 2009, 21(9): 665-667.
doi: 10.1016/j.clon.2009.07.011
|
[19] |
Costa L.
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis[J]. BreastBreast, 2007, 16(Suppl 3): S16-S20.
|
[20] |
Valachis A, Polyzos NP, Georgoulias V, et al.
Lack of evidence for fracture prevention in early breast cancer bisphos-phonate trials: a meta-analysis[J]. Gynecol OncolGynecol Oncol, 2010, 117(1): 139-145.
doi: 10.1016/j.ygyno.2009.12.001
|